We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biosignatures Distinguish Between Fatal Lung Diseases

By LabMedica International staff writers
Posted on 29 May 2012
In the blood of tuberculosis and sarcoidosis patients a complete gene and micro-ribonucleic acid (miRNA) expression profiles have been created together with important inflammatory mediators. More...


It is almost impossible to distinguish between tuberculosis (TB) and sarcoidosis with just a single signature, therefore a set of different biosignatures is better suited for distinguishing between diseased and healthy individuals and, in a further step, between the specific diseases.

Scientists at the Max Planck Institute for Infection Biology (Berlin, Germany) using gene and miRNA expression in blood cells and inflammatory mediators in serum, selected sets of markers characteristic for tuberculosis and sarcoidosis patients. Although both diseases primarily damage the lungs and produce similar symptoms, they have very different causes as TB is caused by an infection with the bacteria Mycobacterium tuberculosis, while sarcoidosis is not contagious.

The two diseases are not only similar clinically but their biosignatures have a number of elements in common. Compared to healthy individuals, most genes in sarcoidosis and tuberculosis patients are regulated in a similar way. The results obtained by the Berlin investigators show that modified biomarkers can be traced back to processes that occur not only in one specific disease, such as immune responses. The immune response therefore draws on the same basic elements in different clinical pictures, and only a few of these elements are specific to a particular disease. These commonalities also reveal to scientists a lot about the general causes and mechanisms underlying many diseases.

In total, around 150 miRNAs shared by both diseases differed from healthy individuals. Only four miRNAs are suitable for distinguishing TB and sarcoidosis patients. The overlap is less pronounced in the profile of inflammatory substances in the blood: while only one of these cytokines is modified equally in TB and sarcoidosis compared to healthy individuals, twelve of these signal mediators are suitable for distinguishing between the two diseases.

A single biosignature is therefore not enough to distinguish between healthy and diseased individuals, and to distinguish between different diseases with a similar clinical phenotype. Although the combination of many genes increases specificity and sensitivity in distinguishing between healthy and diseased individuals, it automatically leads to a lower specificity compared to other clinical pictures.

Stefan H.E. Kaufmann, PhD, a professor at the Max Planck Institute, said, "Of approximately 13,000 genes whose expression differs, depending on whether the individual is healthy or diseased, approximately 9,000 genes are expressed in the same way in both diseases. Only 700 genes differ in their expression between tuberculosis and sarcoidosis patients - but these can be used to unequivocally identify the two diseases."

Related Links:

Max Planck Institute for Infection Biology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.